Exhibit
10.2


 


April
24, 2020


 


Hancock
Jaffe Laboratories, Inc.


70
Doppler


Irvine,
CA 92618


Attn:
Robert A. Berman, Chief Executive Officer


 


Dear
Mr. Berman:


 


This
letter (the “Agreement”) constitutes the agreement between Spartan Capital Securities, LLC (“Spartan”
or the “Placement Agent”) and Hancock Jaffe Laboratories, Inc. (the “Company”), that Spartan
shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection
with in any offering (each, a “Placement”) of securities of the Company during the Term (as hereinafter defined) of
this Agreement. The terms of each Placement and the securities issued in connection therewith shall be mutually agreed upon by
the Company and Spartan and nothing herein implies that Spartan would have the power or authority to bind the Company and nothing
herein implies that the Company shall have an obligation to issue any securities. The initial proposed Placement of securities
is comprised of (i) registered shares (the “Shares”) of the Company’s common stock, par value $0.00001
per share (the “Common Stock”) and (ii) unregistered warrants to purchase shares of Common Stock (the “Warrants”,
together with the Shares the “Securities”). The terms of the Placement and the Securities, including the Company’s
obligation to file a resale registration statement on Form S-1 with regard to the shares of Common Stock underlying the Warrants
for the benefit of the Purchasers (as defined in this sentence), shall be mutually agreed upon by the Company and the purchasers
(each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes
that Spartan would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue
any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers
in connection with the Placement shall be collectively referred to herein as the “Transaction Documents.” The
date of the closing of the Placement shall be referred to herein as the “Closing Date.” The Company expressly
acknowledges and agrees that Spartan’s obligations hereunder are on a “reasonable best efforts” basis only and
that the execution of this Agreement does not constitute a commitment by Spartan to purchase the Securities and does not ensure
the successful placement of the Securities or any portion thereof or the success of Spartan with respect to securing any other
financing on behalf of the Company. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers
on its behalf in connection with the Placement.


 


SECTION
1. COMPENSATION.


 


A.
Cash and Warrant Coverage. At the Closing of each Placement (each, a “Closing”) the Company will pay Spartan: (i)
a cash fee equal to 8% of the gross proceeds received by the Company from the sale of the Securities to investors introduced to
the Company by Spartan, which shall be deemed to include all investors for which Spartan provides executed Transaction Documents
to the Company; and (ii) a number of warrants equal to the quotient obtained by dividing 8.0% of the gross proceeds paid for the
Securities issued by the Company divided by the purchase price paid by the Purchasers for such Securities (the “Placement
Agent Warrant”). The Placement Agent Warrant, in the form attached hereto as Exhibit A hereto, shall be exercisable,
in whole or in part, commencing on a date which is six months and one day after the Closing and expiring on the five-year anniversary
of the Closing at an exercise price per share equal to 100% of the purchase price of the Securities. The Placement Agent Warrant
and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to as the “Placement Agent’s
Securities.”


 


B.
Expense Allowance. Out of the proceeds of each Closing, the Company also agrees to pay Spartan (a) up to $5,000 reasonable out-of-pocket
expenses incurred for which Spartan shall provide the Company with a detailed invoice and (b) $50,000 for fees and expenses of
legal counsel.


 






    	 



    	 



    

 


SECTION
2. REGISTRATION STATEMENT.


 


The
Company represents and warrants to, and agrees with, the Placement Agent that:


 


(A)
The Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement
on Form S-3 (Registration File No. 333-237592) under the Securities Act of 1933, as amended (the “Securities Act”),
which became effective on April 16, 2020, for the registration under the Securities Act of the Securities. At the time of such
filing and as of the filing of the Company’s Form 10-K for the year ended December 31, 2019, the Company met the requirements
of Form S-3 under the Securities Act. Such registration statement meets the requirements set forth in Rule 415(a)(1)(x) under
the Securities Act and complies with said Rule. The Company will file with the Commission pursuant to Rule 424(b) under the Securities
Act, and the rules and regulations (the “Rules and Regulations”) of the Commission promulgated thereunder,
a supplement to the form of prospectus included in such registration statement relating to the placement of the Shares and the
plan of distribution thereof and has advised the Placement Agent of all further information (financial and other) with respect
to the Company required to be set forth therein. Such registration statement, including the exhibits thereto, as amended at the
date of this Agreement, is hereinafter called the “Registration Statement”; such prospectus in the form in
which it appears in the Registration Statement is hereinafter called the “Base Prospectus”; and the supplemented form
of prospectus, in the form in which it will be filed with the Commission pursuant to Rule 424(b) (including the Base Prospectus
as so supplemented) is hereinafter called the “Prospectus Supplement.” Any reference in this Agreement to the
Registration Statement, the Base Prospectus or the Prospectus Supplement shall be deemed to refer to and include the documents
incorporated by reference therein (the “Incorporated Documents”) pursuant to Item 12 of Form S-3 which were
filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on or before the date of
this Agreement, or the issue date of the Base Prospectus or the Prospectus Supplement, as the case may be; and any reference in
this Agreement to the terms “amend,” “amendment” or “supplement” with respect to the Registration
Statement, the Base Prospectus or the Prospectus Supplement shall be deemed to refer to and include the filing of any document
under the Exchange Act after the date of this Agreement, or the issue date of the Base Prospectus or the Prospectus Supplement,
as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements and
schedules and other information which is “contained,” “included,” “described,” “referenced,”
“set forth” or “stated” in the Registration Statement, the Base Prospectus or the Prospectus Supplement
(and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and
other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus or
the Prospectus Supplement, as the case may be. No stop order suspending the effectiveness of the Registration Statement or the
use of the Base Prospectus or the Prospectus Supplement has been issued, and no proceeding for any such purpose is pending or
has been initiated or, to the Company’s knowledge, is threatened by the Commission. For purposes of this Agreement, “free
writing prospectus” has the meaning set forth in Rule 405 under the Securities Act and the “Time of Sale Prospectus”
means the Base Prospectus, or the preliminary prospectus, if any, together with the free writing prospectuses, if any, used in
connection with the Shares sold as part of the Placement, including any documents incorporated by reference therein.


 


(B)
The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules as
required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became
effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable Rules and Regulations
and did not and, as amended or supplemented, if applicable, will not, contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Base Prospectus,
the Time of Sale Prospectus, if any, and the Prospectus Supplement, each as of its respective date, comply in all material respects
with the Securities Act and the Exchange Act and the applicable Rules and Regulations. Each of the Base Prospectus, the Time of
Sale Prospectus, if any, and the Prospectus Supplement, as amended or supplemented, did not and will not contain as of the date
thereof any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. The Incorporated Documents, when they were filed with
the Commission, conformed in all material respects to the requirements of the Exchange Act and the applicable Rules and Regulations,
and none of such documents, when they were filed with the Commission, contained any untrue statement of a material fact or omitted
to state a material fact necessary to make the statements therein (with respect to Incorporated Documents incorporated by reference
in the Base Prospectus or Prospectus Supplement), in light of the circumstances under which they were made not misleading; and
any further documents so filed and incorporated by reference in the Base Prospectus, the Time of Sale Prospectus, if any, or Prospectus
Supplement, when such documents are filed with the Commission, will conform in all material respects to the requirements of the
Exchange Act and the applicable Rules and Regulations, as applicable, and will not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising after
the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein
is required to be filed with the Commission. There are no documents required to be filed with the Commission in connection with
the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be
filed within the requisite time period. There are no contracts or other documents required to be described in the Base Prospectus,
the Time of Sale Prospectus, if any, or Prospectus Supplement, or to be filed as exhibits or schedules to the Registration Statement,
which have not been described or filed as required.


 




    	 



    	 



    

 


(C)
The Company is eligible to use free writing prospectuses in connection with the Shares sold as part of the Placement pursuant
to Rules 164 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule
433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities
Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed,
or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or behalf of or used by the Company
complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations
of the Commission thereunder. The Company will not, without the prior consent of the Placement Agent, prepare, use or refer to,
any free writing prospectus.


 


(D)
The Company has delivered, or will as promptly as practicable deliver, to the Placement Agent complete conformed copies of the
Registration Statement and of each consent and certificate of experts, as applicable, filed as a part thereof, and conformed copies
of the Registration Statement (without exhibits), the Base Prospectus, the Time of Sale Prospectus, if any, and the Prospectus
Supplement, as amended or supplemented, in such quantities and at such places as the Placement Agent reasonably requests. Placement
Agent acknowledges that all such materials as exist on the date of this letter are available on EDGAR. Neither the Company nor
any of its directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering material
in connection with the offering and sale of the Shares pursuant to the Placement other than the Base Prospectus, the Time of Sale
Prospectus, if any, the Prospectus Supplement, the Registration Statement, copies of the documents incorporated by reference therein
and any other materials permitted by the Securities Act.


 


(E)
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this
Agreement, the Transaction Documents with the Purchasers, this Agreement, and the Prospectus Supplement and otherwise to carry
out its obligations hereunder and thereunder. The execution and delivery of each of this Agreement and the Transaction Documents
by the Company and the consummation by it of the transactions contemplated hereby and thereby and under the Prospectus Supplement
have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company,
the Company’s Board of Directors (the “Board of Directors”) or the Company’s stockholders in connection
therewith. This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies, and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.


 


(F)
The execution, delivery and performance by the Company of this Agreement and the transactions contemplated pursuant to the Transaction
Documents and the Prospectus Supplement, the issuance and sale of the Securities and the consummation by it of the transactions
contemplated hereby and thereby to which it is a party do not and will not (i) conflict with or violate any provision of the Company’s
or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii)
conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights
of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit
facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the
Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected,
or (iii) subject to the Required Approvals (as defined in the Transaction Documents), conflict with or result in a violation of
any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect (as defined in the Securities Purchase Agreement).


 




    	 



    	 



    

 


SECTION
3. REPRESENTATIONS AND WARRANTIES INCORPORATED BY REFERENCE. Each of the representations and warranties (together with
any related disclosure schedules thereto) made to the Purchasers in that certain Securities Purchase Agreement dated as of April
24, 2020, between the Company and each Purchaser, is hereby incorporated herein by reference (as though fully restated herein)
and is hereby made to, and in favor of, Spartan.


 


SECTION
4. REPRESENTATIONS OF SPARTAN. Spartan represents and warrants that it is (i) a member in good standing of FINRA, (ii)
registered as a broker/dealer under the Exchange Act, and (iii) licensed as a broker/dealer under the laws of the States applicable
to the offers and sales of Securities by Spartan. Spartan will immediately notify the Company in writing of any change in its
status as such. Spartan covenants that it will use its “reasonable best efforts” to conduct the Placement hereunder
in compliance with the provisions of this Agreement and the requirements of applicable law. Except as required by law or as contemplated
by this Agreement, Spartan will keep confidential all material nonpublic information, including information regarding the Placement
contemplated hereunder, provided to it by the Company or its affiliates or advisors and use such information only for the purposes
contemplated herein.


 


SECTION
5. INDEMNIFICATION. The Company agrees to the indemnification and other agreements set forth in the Indemnification
Provisions (the “Indemnification”) attached hereto as Addendum A, the provisions of which are incorporated
herein by reference and shall survive the termination or expiration of this Agreement.


 


SECTION
6. ENGAGEMENT TERM. Spartan’s engagement hereunder will be for 45 days following the date hereof (the “Term”).
Following the expiration of the Term, the engagement may be terminated by either the Company or Spartan at any time upon written
notice to the other party. The Company and Spartan specifically agree that termination of Spartan’s engagement with respect
to the Placement will not affect the parties’ obligations to each other with respect to any other agreements entered into
by the parties since January 1, 2020. Notwithstanding anything to the contrary contained herein, the provisions concerning the
Company’s obligation to pay any fees actually earned and to reimburse expenses actually incurred and reimbursable pursuant
to Section 1 hereof and which are permitted to be reimbursed under FINRA Rule 5110(f)(2)(D), and the confidentiality, indemnification,
contribution provisions contained herein and the Company’s obligations contained in the Indemnification Provisions will
survive any expiration or termination of this Agreement. Spartan agrees not to disclose or use any confidential information concerning
the Company provided to it by the Company for any purposes other than those contemplated under this Agreement or any other agreements
entered into by Spartan and the Company since January 1, 2020.


 


SECTION
7. SPARTAN INFORMATION. The Company agrees that any information or advice rendered by Spartan in connection with this
engagement is for the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required
by law, the Company will not disclose or otherwise refer to the advice or information in any manner without Spartan’s prior
written consent.


 


SECTION
8. NO FIDUCIARY RELATIONSHIP. This Agreement does not create, and shall not be construed as creating rights enforceable
by any person or entity not a party hereto, except those entitled hereto by virtue of the Indemnification Provisions hereof. The
Company acknowledges and agrees that Spartan is not and shall not be construed as a fiduciary of the Company and shall have no
duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue of this Agreement or
the retention of Spartan hereunder, all of which are hereby expressly waived.


 


SECTION
9. CLOSING. The Closing shall occur at the offices of the Placement Agent (or at such other place as shall be agreed
upon by the Placement Agent and the Company). Subject to the terms and conditions hereof, at each Closing payment of the purchase
price for the Securities sold on such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities,
and such Securities shall be registered in such name or names and shall be in such denominations, as provided for in the Transaction
Documents or otherwise as the Placement Agent may request at least one business day before the Closing. The obligations of the
Placement Agent, and the closing of the sale of the Securities hereunder are subject to the accuracy, when made and on the Closing
Date, of the representations and warranties on the part of the Company and its Subsidiaries contained herein, to the accuracy
of the statements of the Company and its Subsidiaries made in any certificates pursuant to the provisions hereof, to the performance
by the Company and its Subsidiaries of their obligations hereunder, and to each of the following additional terms and conditions:


 


(A)
No stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose
shall have been initiated or threatened by the Commission, and any request for additional information on the part of the Commission
(to be included in the Registration Statement, the Base Prospectus or the Prospectus Supplement or otherwise) shall have been
complied with to the reasonable satisfaction of the Placement Agent.


 






    	 



    	 



    

 


(B)
The Placement Agent shall not have discovered and disclosed to the Company on or prior to the Closing Date that the Registration
Statement, the Base Prospectus or the Prospectus Supplement or any amendment or supplement thereto contains an untrue statement
of a fact which, in the opinion of counsel for the Placement Agent, is material or omits to state any fact which, in the opinion
of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading.


 


(C)
All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each
of this Agreement, the Securities, the Registration Statement, the Base Prospectus and the Prospectus Supplement and all other
legal matters relating to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material
respects to counsel for the Placement Agent, and the Company shall have furnished to such counsel all documents and information
that they may reasonably request to enable them to pass upon such matters.


 


(D)
The Placement Agent shall have received from outside counsel to the Company such counsel’s written opinion, addressed to
the Placement Agent and the Purchasers dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement
Agent.


 


(E)
(i) Neither the Company nor any of its Subsidiaries shall have sustained since the date of the latest audited or unaudited financial
statements included or incorporated by reference in the Base Prospectus, any loss or interference with its business from fire,
explosion, flood, terrorist act or other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than as set forth in or contemplated by the Base Prospectus of Prospectus Supplement
and (ii) since such date there shall not have been any change in the capital stock or long-term debt of the Company or any of
its Subsidiaries or any change, or any development involving a prospective change, in or affecting the business, general affairs,
management, financial position, stockholders’ equity, results of operations or prospects of the Company and its Subsidiaries,
otherwise than as set forth in or contemplated by the Base Prospectus or Prospectus Supplement, the effect of which, in any such
case described in clause (i) or (ii), is, in the judgment of the Placement Agent, so material and adverse as to make it impracticable
or inadvisable to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated by the Base
Prospectus, the Time of Sale Prospectus, if any, and the Prospectus Supplement.


 


(F)
The Common Stock is registered under the Exchange Act. The Company shall have taken no action designed to, or likely to have the
effect of terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any information
suggesting that the Commission is contemplating terminating such registration. The Common Stock shall be registered under the
Exchange Act and shall be listed on the Nasdaq Capital Market, LLC, and the Company shall not have taken any action designed to
terminate, or likely to have the effect of terminating, the registration of the Common Stock under the Exchange Act or delisting
or suspending from trading the Common Stock from Nasdaq Capital Market, LLC, and, other than as publicly disclosed by the Company
in filings with the Commission filed since January 1, 2019, nor shall the Company have received any information suggesting that
the Commission or Nasdaq Capital Market, LLC is contemplating terminating such registration or listing other than as publicly
disclosed by the Company in filings with the Commission.


 


(G)
Subsequent to the execution and delivery of this Agreement, there shall not have occurred any of the following: (i) trading in
securities generally on the New York Stock Exchange or The Nasdaq National Market shall have been suspended or minimum or maximum
prices or maximum ranges for prices shall have been established on any such exchange or such market by the Commission, by such
exchange or by any other regulatory body or governmental authority having jurisdiction, (ii) a banking moratorium shall have been
declared by federal or state authorities or a material disruption has occurred in commercial banking or securities settlement
or clearance services in the United States, (iii) the United States shall have become engaged in hostilities in which it is not
currently engaged, the subject of an act of terrorism, there shall have been an escalation in hostilities involving the United
States, or there shall have been a declaration of a national emergency or war by the United States, or (iv) there shall have occurred
any other calamity or crisis or any change in general economic, political or financial conditions in the United States or elsewhere,
if the effect of any such event in clause (iii) or (iv) makes it, in the sole judgment of the Placement Agent, impracticable or
inadvisable to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated by the Base Prospectus
and the Prospectus Supplement.


 




    	 



    	 



    

 


(H)
No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental
agency or body which would, as of the Closing Date, prevent the issuance or sale of the Securities or materially and adversely
affect or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or
order of any other nature by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date
which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially and adversely affect
the business or operations of the Company.


 


(I)
The Company shall have prepared and filed with the Commission a Current Report on Form 8-K with respect to the Placement, including
as an exhibit thereto this Agreement.


 


(J)
The Company shall have entered into subscription agreements with each of the Purchasers and such agreements shall be in full force
and effect and shall contain representations, warranties and covenants of the Company as agreed between the Company and the Purchasers.


 


(K)
FINRA shall have raised no objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition,
the Company shall, if requested by the Placement Agent, make or authorize Placement Agent’s counsel to make on the Company’s
behalf, an Issuer Filing with FINRA pursuant to FINRA Rule 5110 with respect to the Registration Statement and pay all filing
fees required in connection therewith.


 


(L)
Prior to the Closing Date, the Company shall have furnished to the Placement Agent such further information, certificates and
documents as the Placement Agent may reasonably request, including a certificate of the Chief Financial Officer with respect to
certain financial information set forth in the Company’s public reports.


 


(M)
Prior to the Closing Date, the Company shall have furnished to the Placement Agent a certificate, dated the Closing Date, of its
Chief Executive Officer and its Chief Financial Officer stating that (i) such officers have carefully examined the Registration
Statement, the Base Prospectus and the Prospectus Supplement and, in their opinion, Registration Statement, as of its effective
date, did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading, and the Registration Statement, the Base Prospectus or the
Prospectus Supplement, as of the time of execution of this Agreement through the Closing Date, did not include any untrue statement
of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances in which they were made, not misleading, (ii) since the filing of the most recent Form 10-K, no event has occurred
which should have been set forth in a supplement or amendment to the Registration Statement, the Base Prospectus or the Prospectus
Supplement, and (iii) to their knowledge after reasonable investigation, as of the Closing Date, the representations and warranties
of the Company in this Agreement are true and correct, and the Company has complied with all agreements and satisfied all conditions
on its part to be performed or satisfied hereunder at or prior to the Closing Date.


 


(N)
As of the Closing Date, the Placement Agent shall have received a certificate of the Company signed by the Secretary of the Company,
dated the Closing Date, certifying: (i) that each of the Company’s certificate of incorporation and bylaws is true and complete,
has not been modified and is in full force and effect; (ii) that the resolutions of the Company’s Board of Directors relating
to the Placement are in full force and effect and have not been modified; and (iii) the good standing of the Company and its subsidiaries.
The documents referred to in such certificate shall be attached to such certificate.


 


All
opinions, letters, evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance
with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Placement Agent.


 




    	 



    	 



    

 


SECTION
10. GOVERNING LAW. This Agreement will be governed by, and construed in accordance with, the laws of the State of New
York applicable to agreements made and to be performed entirely in such State. This Agreement may not be assigned by either party
without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties
hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising
under this Agreement or any transaction or conduct in connection herewith is waived. Each of the Placement Agent and the Company:
(i) agrees that any legal suit, action or proceeding arising out of or relating to this Agreement and/or the transactions contemplated
hereby shall be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court for
the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action
or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New York, and the United
States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Placement Agent
and the Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit,
action or proceeding in the New York Supreme Court, County of New York, or in the United States District Court for the Southern
District of New York and agrees that service of process upon the Company mailed by certified mail to the Company’s address
shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service
of process upon the Placement Agent mailed by certified mail to the Placement Agent’s address shall be deemed in every respect
effective service process upon the Placement Agent, in any such suit, action or proceeding. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. If either party shall commence an action
or proceeding to enforce any provisions of a Transaction Document, then the prevailing party in such action or proceeding shall
be reimbursed by the other party for its attorneys fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.


 


SECTION
11. ENTIRE AGREEMENT/MISC. This Agreement (including the attached Indemnification Provisions) embodies the entire agreement
and understanding between the parties hereto, and supersedes all prior agreements and understandings, relating to the subject
matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination
will not affect such provision in any other respect or any other provision of this Agreement, which will remain in full force
and effect. This Agreement may not be amended or otherwise modified or waived except by an instrument in writing signed by both
Spartan and the Company. The representations, warranties, agreements and covenants contained herein shall survive the closing
of the Placement and delivery and/or exercise of the Securities, as applicable. This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when
counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign
the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or .pdf signature page were an original thereof. The Company agrees that the Placement Agent
may rely upon, and is a third party beneficiary of, the representations and warranties, and applicable covenants set forth in
any such purchase, subscription or other agreement with the Purchasers in the Placement.


 


SECTION
12. CONFIDENTIALITY. The Placement Agent (i) will keep the Confidential Information (as such term is defined below)
confidential and will not (except as required by applicable law or stock exchange requirement, regulation or legal process), without
the Company’s prior written consent, disclose to any person any Confidential Information, and (ii) will not use any Confidential
Information other than in connection with its evaluation of the Transaction. The Placement Agent further agrees to disclose the
Confidential Information only to its Representatives who need to know the Confidential Information for the purpose of evaluating
the Transaction, and who are informed by the Placement Agent of the confidential nature of the Confidential Information. The term
“Confidential Information” shall mean, all confidential, proprietary and non-public information (whether written,
oral or electronic communications) furnished by the Company to the Placement Agent or its Representatives in connection with the
Placement Agent’s evaluation of the Transaction, which information is (a) clearly marked as “confidential” or
with a similar designation, or (b) if disclosed orally or otherwise than in writing, is identified as confidential and/or proprietary
at the time of disclosure by the Company. Information communicated orally or otherwise than in writing, shall only be considered
Confidential Information if such information is designated as being confidential at the time of disclosure (or promptly thereafter)
and is reduced in writing and identified to the Placement Agent as being Confidential Information immediately after the initial
disclosure. The term “Confidential Information” will not, however, include information which (i) is or becomes
publicly available other than as a result of a disclosure by the Placement Agent or its Representatives in violation of this Agreement,
or (ii) is known to the Placement Agent or any of its Representatives prior to disclosure by the Company or any of its Representatives.
The term “Representatives” shall mean a party’s directors, board committees, officers, employees, financial
advisors, attorneys and accountants. This provision shall be in full force and effect for two years.


 


SECTION
13. NOTICES. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number specified on the signature pages attached hereto prior to 6:30
p.m. (New York City time) on a business day, (b) the next business day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number on the signature pages attached hereto on a day that is not a business day
or later than 6:30 p.m. (New York City time) on any business day, (c) the business day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.


 


[The
remainder of this page has been intentionally left blank.]


 




    	 



    	 



    

 


Please
confirm that the foregoing correctly sets forth our agreement by signing and returning to Spartan the enclosed copy of this Agreement.


 


	 	Very
    truly yours,
	 	 
	 	SPARTAN
    CAPITAL SECURITIES, LLC
	 	 
	 	By:	                                        
	 	Name:	Jason
Diamond
	 	Title:	Head
    of Investment Banking
	 	 
	 	Addresses
    for notice:
	 	Spartan
    Capital Securities, LLC
	 	789
    N. Water Street, Suite 400
	 	Milwaukee,
    WI 53202
	 	Attention:
    Jason Diamond
	 	Email:
    jdiamond@spartancapital.com


 


	 	Spartan
    Capital Securities, LLC
	 	45
    Broadway
	 	New
    York, NY 10006
	 	Attn:
    Kim Monchik
	 	kmonchik@spartancapital.com
	 	 
	 	with
    a copy that shall not constitute notice to:
	 	Lucosky
    Brookman LLP
	 	101
    Wood Avenue South
	 	Iselin,
    NJ 08830


 


Accepted
and Agreed to as of


the
date first written above:


 


	Hancock
    Jaffe Laboratories, Inc.	 
	 	 
	By:	 	 
	Name:	Robert
    A Berman	 
	Title:	Chief
    Executive Officer	 


 


Address
for notice:


Hancock
Jaffe Laboratories, Inc.


70
Doppler


Irvine,
CA 92618


Attn:
Robert A Berman, Chief Executive Officer


 




    	 



    	 



    

 


ADDENDUM
A


 


INDEMNIFICATION
PROVISIONS


 


In
connection with the engagement of Spartan Capital Securities, LLC (“Spartan”) by Hancock Jaffe Laboratories,
Inc. (the “Company”) pursuant to a letter agreement dated April 24, 2020, between the Company and Spartan,
as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:


 


	1.	The
    Company hereby agrees to indemnify and hold Spartan, its officers, directors, principals, employees, affiliates, and stockholders,
    and their successors and assigns, harmless from and against any and all loss, claim, damage, liability, deficiencies, actions,
    suits, proceedings, costs and legal expenses or expense whatsoever (including, but not limited to, reasonable legal fees and
    other expenses and reasonable disbursements incurred in connection with investigating, preparing to defend or defending any
    action, suit or proceeding, including any inquiry or investigation, commenced or threatened, or any claim whatsoever, or in
    appearing or preparing for appearance as witness in any proceeding, including any pretrial proceeding such as a deposition)
    (collectively the “Losses”) arising out of, based upon, or in any way related or attributed to, (i) any breach
    of a representation, warranty or covenant by the Company contained in this Agreement; (ii) the Registration Statement, the
    Base Prospectus, or the Prospectus Supplement (as from time to time each may be amended and supplemented); (iii) any materials
    or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Placement,
    including any “road show” or investor presentations made to investors by the Company (whether in person or electronically);
    or (iv) any activities or services performed hereunder by Spartan, unless it is finally judicially determined in a court of
    competent jurisdiction that such Losses were the primary and direct result of the intentional misconduct or gross negligence
    of Spartan in performing the services hereunder or information provided by Spartan expressly for inclusion in the Prospectus
    Supplement.
	 	 
	2.	If
    Spartan receives written notice of the commencement of any legal action, suit or proceeding with respect to which the Company
    is or may be obligated to provide indemnification pursuant to this Section (B), Spartan shall, within twenty (20) days of
    the receipt of such written notice, give the Company written notice thereof (a “Claim Notice”). Failure
    to give such Claim Notice within such twenty (20) day period shall not constitute a waiver by Spartan of its right to indemnity
    hereunder with respect to such action, suit or proceeding; provided, however, the indemnification hereunder may be limited
    by any such failure to provide a Claim Notice to the Company that materially prejudices the Company. Upon receipt by the Company
    of a Claim Notice from Spartan with respect to any claim for indemnification which is based upon a claim made by a third party
    (“Third Party Claim”), the Company may assume the defense of the Third Party Claim with counsel reasonably
    satisfactory to Spartan, as described below. Spartan shall cooperate in the defense of the Third Party Claim and shall furnish
    such records, information and testimony and attend all such conferences, discovery proceedings, hearings, trial and appeals
    as may be reasonably required in connection therewith. Spartan shall have the right to employ its own counsel in any such
    action which shall be at the Company’s expense if (i) the Company and Spartan shall have mutually agreed in writing
    to the retention of such counsel, (ii) the Company shall have failed in a timely manner to assume the defense and employ counsel
    or experts reasonably satisfactory to Spartan in such litigation or proceeding or (iii) the named parties to any such litigation
    or proceeding (including any impleaded parties) include the Company and Spartan and representation of the Company and Spartan
    by the same counsel or experts would, in the reasonable opinion of Spartan, be inappropriate due to actual or potential differing
    interests between the Company and Spartan. The Company shall not satisfy or settle any Third Party Claim for which indemnification
    has been sought and is available hereunder, without the prior written consent of Spartan, which consent shall not be delayed
    and which shall not be required if Spartan is granted an unconditional release in connection therewith in such form as reasonably
    acceptable to Spartan, and if such release does not include a statement as to or an admission of fault, culpability or a failure
    to act, by or on behalf of Spartan, or its officers, directors, principals, employees, affiliates, and stockholders. The indemnification
    provisions hereunder shall survive the termination or expiration of this Agreement.


 




    	 



    	 



    

 


	3.	The
    Company further agrees, upon demand by Spartan, to promptly advance and/or reimburse Spartan for, or pay, any loss, claim,
    damage, liability or expense as to which Spartan has been indemnified herein with such reimbursement to be made currently
    as any loss, damage, liability or expense is incurred by Spartan. Notwithstanding the provisions of the aforementioned Indemnification,
    any such advancement, reimbursement or payment by the Company of fees, expenses, or disbursements incurred by Spartan shall
    be repaid by Spartan in the event of any proceeding in which a final judgment (after all appeals or the expiration of time
    to appeal) is entered in a court of competent jurisdiction against Spartan based solely upon its gross negligence or intentional
    misconduct in the performance of its duties hereunder or the information provided by Spartan expressly for inclusion in the
    Prospectus Supplement, and provided further, that the Company shall not be required to make reimbursement or payment for any
    settlement effected without the Company’s prior written consent (which consent shall not be unreasonably withheld or
    delayed).
	 	 
	4.	If
    for any reason the foregoing indemnification is unavailable or is insufficient to hold such indemnified party harmless, the
    Company agrees to contribute the amount paid or payable by such indemnified party in such proportion as to reflect not only
    the relative benefits received by the Company, as the case may be, on the one hand, and Spartan, on the other hand, but also
    the relative fault of the Company and Spartan as well as any relevant equitable considerations. In no event shall Spartan
    contribute in excess of the fees actually received by it pursuant to the terms of this Agreement.
	 	 
	5.	For
    purposes of this Agreement, each officer, director, stockholder, and employee or affiliate of Spartan and each person, if
    any, who controls Spartan (or any affiliate) within the meaning of either Section 15 of the Securities Act of 1933, as amended,
    or Section 20 of the Securities Exchange Act of 1934, as amended, shall have the same rights as Spartan with respect to matters
    of indemnification by the Company hereunder.


 


	 	SPARTAN
    CAPITAL SECURITIES, LLC
	 	 	 
	 	Name: 	Jason
    Diamond
	 	Title:	Head
    of Investment Banking


 


Accepted
and Agreed to as of


the
date first written above:


 


	Hancock
    Jaffe Laboratories, Inc.	 
	 	 
	By:	 	 
	Name: 	Robert
    A Berman	 
	Title:	Chief
    Executive Officer